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1. Introduction
T-cell leukemias and lymphomas are a heterogeneous group of uncommon tumors that
account for 7-15% of lymphomas. [1] They represent approximately 6,500 new cases annually
in the United States. Typically patients with malignant T-cell disorders present with high-
grade lesions, advanced stage disease and have systemic or “B” symptoms at diagnosis. Until
relatively recently these diseases were treated with the same anthracycline-based chemother‐
apy regimens used to treat B-cell lymphomas. With few exceptions, the outcomes are poorer
with lower response rates, shorter times to progression, and shorter median survivals com‐
pared to B-cell lymphomas. A number of new agents have recently entered the clinic for the
treatment of T-cell lymphomas. [2] These include the histone deacetylase inhibitors voronistat
(Zolinza®) and romidepsin (Istodax®) approved for treatment of previously treated cutaneous
T-cell lymphoma (CTCL), the antifolate, pralatrexate (Fotolyn®) indicated for the treatment of
relapsed or resistant peripheral T-cell lymphoma (PTCL), and the immunotoxin brentuximab
vedotin (Adcetris®) for the treatment of relapsed anaplastic large cell lymphoma (ALCL).
These newer agents join a handful of drugs approved for the treatment of T-cell lymphomas
including beraxotene (Targretin®) and the interleukin-2-diphtheria toxin fusion protein,
denileukin diftitox (Ontak®).
The introduction of the chimerized anti-CD20 monoclonal antibody, rituximab (Rituxan®),
was a major advance in the treatment of B-cell lymphoma improving the survival of patients
with B-cell lymphoma. Unlike B-cell lymphomas no monoclonal antibody has received a
similar indication for treatment of T-cell neoplasms. Presently an expanding number of
antibodies targeting T-cells are being studied for the treatment of T-cell leukemia and lym‐
phoma. The current status of monoclonal antibody therapy of T-cell leukemia and lymphoma
will be the focus of this chapter.
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Target Antigen Description Monoclonal Antibody
CD2 LFA-3 (CD58) Slipizumab (MEDI-507)
CD3 (CD3ζ) TcR signaling chain muromonab-CD3 (Orthoclone®, OKT3)
CD4 TcR co-receptor Zanolimumab (HuMax-CD4®)
CD5 Scavenger receptor family member Anti-Leu1
T101
CD25 IL-2 receptor α-subunit Daclizumab (Zenapax®)
CD30 TNF receptor family member Brentuximab vedotin (Adcetris®)
CD52 GPI-anchored glycoprotein Alemtuzumab (Campath®)
CD122 β-subunit of the IL-2 and IL-15
receptor
Mik-β1
CCR4 Chemokine receptor-4 KW-0761
Table 1. Monoclonal antibodies for the treatment of T-cell leukemia and lyumphoma.
2. Characteristics of the ideal target for antibody-directed therapy
Delivering maximum therapeutic benefits with minimal or no toxicity have been the main
objective of any therapeutic strategy including antibody therapy. The choice of therapeutic
target for antibody therapy is one of the most important variables in achieving this goal. The
ideal target for antibody-directed therapy should have following characteristics: Including
restriction of the target antigen expression to malignant T-cells. Toxicity and unintended
effects of a ubiquitously present target is a significant hindrance in development of antibody
therapy, an ideal target should have its expression restricted to malignant T-cell or if the target
is expressed on other hematopoietic cells, the loss of these cells or their function should not
result in serious complications such as life-threatening immunosuppression. If the target is
broadly expressed on other T-cells or hematopoietic cells, treatment will not only eliminate
the tumor cells, it will also cause depletion of functional T-cells allowing reactivation or
susceptibility to a variety of serious infections. Alemtuzumab (Campath®), a monoclonal
antibody directed against CD52 is an effective therapy against B-cell chronic lymphocytic
leukemia (CLL); however, since CD52 is also expressed on T-cells, treatment results in the
depletion of both CD4+ and CD8+ T-cell populations and an increased risk of opportunistic
infections. [3]
The target antigen ideally should be expressed at high density on the malignant T-cells. Most
antibodies deliver their therapeutic effect by binding to the target on the cell surface, activating
complement, antibody dependent cellular cytotoxicity (ADCC) or inducing signals activating
apoptosis. The target receptor must be present in significant numbers on the cell surface to
provide an adequate number of binding sites for the antibody. Down modulation and
mutations in surface receptors can reduce binding of monoclonal antibodies interfering with
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their therapeutic efficacy. Modulation of surface receptor expression is an important physio‐
logical characteristic used by normal and malignant cells to control responsiveness to cytokines
and other receptor ligands. For unmodified monoclonal antibodies ideally the antibody target
should be non-modulating so that adequate target antigen is always available for antibody to
exert its therapeutic effect. Modulating receptors internalize antibody-receptor complex
leaving limited numbers of surface receptors causing relative resistance. Modulation; however,
can be used to an advantage with immunotoxins and ligand-toxin fusion proteins that need
internalization to exert their action, but in general, modulation reduces the effectiveness of
monoclonal antibodies.
Other characteristics of the ideal monoclonal antibody should include that the targeting of the
antigen by the antibody should not lead to serious side effects. In addition to their immuno‐
genicity causing infusion reactions and serum sickness, some monoclonal antibodies can
stimulate the systemic release of inflammatory cytokines with serious consequences. A phase
1 dose-escalation trial testing an anti-CD28 monoclonal antibody (TGN1412) with ‘super-
agonist’ effects on T-lymphocytes caused near-lethal acute systemic inflammation requiring
hospitalization in six volunteers treated in a phase I study. [4]
3. Qualities of the antibody
Ideally the targeting antibody itself should be non-immunogenic, should act through several
mechanisms of antitumor activity and have patient friendly dosing schedules and pharmaco‐
kinetics. [5] Current technologies has made it possible to engineer majority of antibodies in
clinical use so that most of the molecule except for the receptor-binding domains is identical
to that of a human antibody to reduce immunogenicity and the risk of neutralizing responses
against the antibody. [6, 7]
3.1. Mechanism of action
Mechanisms of actions of monoclonal antibody action include induction of antibody-depend‐
ent cellular cytotoxicity (ADCC). A monoclonal antibody binds to its antigen target and
recruits other components of cellular immune system such as NK cells, neutrophils, and
eosinophils. These stimulated cells then attack and destroy the tumor cell. Some antibodies
will directly bind to Fc receptors on effector cells such as macrophages and cytolytic T-cells
causing destruction of the target cell through ADCC. [8]
Complement-mediated cytotoxicity (CMC) is another Fc-mediated mechanism of monoclonal
antibody action. [9] It has been shown to play a roll in the antitumor activity of a number of
antibodies including alemtuzumab. [10] In addition to CMC, complement fixation is also
involved in inflammation, chemotaxis and opsonization, all of which may aid in tumor cell
killing.
Monoclonal antibodies can also engage tumor cell surface receptors resulting into release of




those of the tumor necrosis factor receptor (TNFR) family, Fas, and the receptors for TNF-
related apoptosis-inducing ligand (TRAIL) when engaged by their ligand deliver an apoptotic
signal promoting apoptosis. Monoclonal antibodies can mimic the physiologic ligand of these
receptors and can agonistically bind to receptor family members eliciting apoptotic responses
on engagement. [11] A number of monoclonal antibodies are known to induce tumor cell
apoptosis at least partially through direct engagement of their target receptor including
SGN-30 a chimeric anti-CD30 antibody, and alemtuzumab (anti-CD52). [12, 13]
Monoclonal antibodies can also hinder cell growth and regulation through blocking critical
ligand-receptor interactions necessary for tumor survival and inducing receptor and down-
modulation reducing pro-growth signaling. Daclizumab, the anti-CD25 antibody, exert its
main cytotoxic effect by blocking the binding of IL-2 to its receptors depriving T-cells of a
necessary growth factor resulting in cell death. [14]
3.2. Immunogenicity of monoclonal antibodies
3.2.1. Non-human monoclonal antibodies
Scientists have attempted to produce single specificity monoclonal antibodies for therapy for
more than a century now. Despite early optimism the development of monoclonal antibodies
as therapeutic modality remained elusive due to the immunogenicity of monoclonal antibod‐
ies. It was only with the introduction of hybridoma technology in 1975 the promise of selec‐
tively targeting cancers using monoclonal antibodies became a reality. [15] Early therapeutic
monoclonal antibodies were derived primarily from rodents. These antibodies can be pro‐
duced in large amounts and have greater specificity to their single antigenic determinant
compared to polyclonal antisera used for therapeutic purposes. Unfortunately early attempts
to use these mouse or rodent antibodies for therapeutic purposes were unsuccessful in large
part due to the dissimilarity between the rodent and human immune systems. Initially
developed non-human antibodies, as foreign glycoproteins, had several issues hindering their
effectiveness and development. These rodent hybridoma-derived antibodies exhibited short
in vivo half-lives, were highly immunogenic in man often inducing neutralizing human anti-
mouse antibodies (HAMA), and they could not engage Fc receptors expressed on human
effector cells resulting in their inability at inducing ADCC making them relatively weak
cytotoxic agents. Due to the foreign protein sequences serum sickness, infusion reactions and
anaphylaxis were also common with these antibodies. In addition, many of these early non-
human monoclonal antibodies were not directed against cell surface targets that were acces‐
sible to the antibody limiting their efficacy. First FDA approved monoclonal antibody in 1986
for treatment of allogeneic transplant rejection, Muromonab-CD3 (Orthoclone® OKT3), an
anti-CD3 monoclonal antibody, is a non-human monoclonal antibody. [16]
3.2.2. Chimerized antibodies
Rapid neutralization of therapeutic antibodies due to formation of immune complexes
between the non-human monoclonal antibody and induced host antibodies can severely limit
tumor response and may alter antibody distribution and binding resulting in undesired side
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effects. Engineering of non-human monoclonal antibodies with human constant domains, so
called chimerized or humanized monoclonal antibodies, or the generation of fully human
monoclonal antibodies using transgenic or phage display technology has helped overcome
many of these issues of immunogenicity. [17-19]
Chimeric monoclonal antibodies are generated by linking the rodent light and heavy chain
variable domains to the human immunoglobulin constant domains using recombinant DNA
technology. [20] This results in an antibody that contains approximately 65% human sequences
that exhibits reduced immunogenicity and an increased serum half-life. Although the immu‐
nogenicity of chimeric monoclonal antibodies is significantly reduced, they are occasionally
still capable of eliciting a human anti-chimera response (HACA) in some patients.
3.2.3. Chimerized monoclonal antibodies
Second generation monoclonal antibodies were further improved by incorporating the six
complementarity-determining regions (CDR) of the rodent antibody-antigen binding site onto
a human IgG antibody framework. Further improvements in maintaining the structure of the
antigen-binding site and high affinity binding to the target were made by incorporating small
number of amino acids in the murine antibody not directly involved in the CDR. [21] Alem‐
tuzumab is one such example. Although the binding between humanized antibodies and the
dissociation constants (Kd) of humanized and the parental monoclonal antibody target is
weaker than the murine parent, the differences between these are usually small enough to not
be significant. [22, 23] Polymorphisms located in the constant regions, or to anti-idiotypic
recognition of the variable domain can rarely result in human anti-human (HAHA) antibody
responses. [24, 25]
3.2.4. Fully human monoclonal antibodies
To further enhance efficacy, “fully human” monoclonal antibodies have been generated using
transgenic mice expressing human immunoglobulin genes. Vaccination of these mice using
the desired antigen induces B-cells producing a fully human antibody by the mouse. Panitu‐
mumab (Vectibix®) an anti-EGFR monoclonal antibody [26], and ofatumumab (Azerra®), an
anti-CD20 monoclonal antibody, were generated using such an approach. Phage display
technology has also made it possible to develop fully human monoclonal antibody with
significant clinical activity. Phage display techniques have the added benefit of also allowing
the enhanced selection of therapeutically relevant features of antibodies. [27]
3.3. Fully human monoclonal antibodies
Most antibodies in clinical use exert their antitumor effect through direct antibody-mediated
killing. In an effort to increase cytotoxic effect of monoclonal antibodies other modifications
were made to enhance their affinity or cell toxicity by combining the antibody with a toxin or
radioisotope.
The antibody Fc region mediates effector function and may be altered to augment binding to




ADCC. One strategy is to engineer Fc portions that exhibit reduced fucose glycosylation. [28]
Alternatively, the Fc region may be engineered to reduce or enhance CMC by substituting
antibody isotypes such as IgG4 that exhibit little complement activation or Fc receptor binding.
An additional interaction of the Fc region is with the neonatal receptor FcRn that is involved
with immunoglobulin turnover. This receptor interacts with IgG Fc in a saturable and pH
dependent manner, this allows FcRn to bind IgG from acidic endosomes generated during
pinocytosis, and recycle the IgG back to the cell surface where it is released in the slightly basic
pH of the blood. This allows for an extended antibody half-life. This approach holds much
promise for favorably altering the pharmacokinetics of monoclonal antibodies ultimately
leading to the potential for less frequent administration of these expensive treatments.
3.4. Immunotoxins
Immunotoxins are conjugations of monoclonal antibodies with toxins that result in highly
specific cytotoxicity. In this approach it is desirable for the target antigen to be internalized
upon antibody binding delivering the toxin into the cell. These toxins, often derived from
bacteria or plants sources, are extremely potent. Bacterial toxins such as diphtheria toxin (DT)
and Pseudomonas exotoxin A inhibit cellular protein synthesis by the irreversible ADP ribosy‐
lation of elongation factor-2 (EF-2), while plant toxins such as ricin inactivate ribosomes. [29]
Disadvantages of this approach include the increased immunogenicity of most of these toxins
because of their microbial or plant origins. In addition, many immunotoxin conjugates are non-
specifically taken up by pinocytocysis by endothelial cell resulting in a vascular leak syndrome
with edema and weight gain. In 2011, Brentuximab vendotin (Adcetris®), an immunotoxin
composed of an anti-CD30 monoclonal antibody (SGN-30) and the potent anti-microtubule
agent monomethylauristatin (MMAE) was approved for previously treated anaplastic large
cell lymphoma and Hodgkin’s lymphoma. [30] Denileukin difitox (Ontak®) approved for the
treatment cutaneous T-cell lymphoma is often categorized as an immunotoxin; however, this
agent is not antibody-based, but rather represents a fusion protein between the receptor
binding domain of interleukin-2 and diphtheria toxin linked by short peptide sequence. [31]
3.5. Radioimmunotherapy
Radioimmunotherapy combines the specificity of monoclonal antibodies with the tumor
killing effects of radiation, in theory sparing non-target cells from exposure to high doses of
radiation. The choice of an appropriate antigen target and hence the specific monoclonal
antibody is critical, as off target killing needs to be avoided. One consequence of this is the
“bystander” or “cross-fire” effect, as radiation can also kill adjacent tumor cells that may not
express the target antigen. The greatest clinical experience with radioimmunotherapy is in
CD20-expressing lymphomas using radionuclides such as yttrium-90 (90Y) and iodine-131 (131I)
labeled anti-CD20 monoclonal antibodies.
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4. Antibody therapy for T-cell leukemias and lymphomas
4.1. Anti-CD2 antibodies
CD2 is a surface glycoprotein that plays a key role in lymphocyte adhesion and signaling. [32]
It is expressed on human T-lymphocytes, natural killer (NK) cells, and thymocytes, and its
stimulation results in T-cell activation and antigen co-stimulation. It also potentiates the
physical interaction between T-cells and antigen presenting cells, as well as between T-cells
and NK-cells. In the cell membrane, CD2 associates with the T-cell receptor (TcR) and appears
to enhance CD3 signaling during low affinity interactions with the major histocompatibility
complex (MHC) molecules enhancing class I and class II-restricted antigen recognition. [33]
Siplizumab is humanized IgG1 monoclonal antibodies that binds to CD2 and inhibits T-
cell  responses  and induced severe  T-cell  lymphopenia.  It  has  primarily  been studied as
treatment  for  refractory  psoriasis  and  treatment  for  graft-versus-host  disease  occurring
during allogeneic bone marrow transplant. It has shown to increase disease-free survival of
mice inoculated with human MET-1 adult T-cell leukemia cells. [34] In a phase I/II trial [35],
29  patients  with  various  T-cell  malignancies  including  HTLV-1-associated  adult  T-cell
leukemia, peripheral T-cell lymphoma, cutaneous T-cells lymphoma, T-cell chronic lympho‐
cytic leukemia, and T-cell large granular lymphocyte leukemia were treated with siplizu‐
mab. Twenty-eight patients experienced a marked decline in circulating CD4+ and CD8+ T-
cells, and NK-cells and there were two complete and nine partial responses. Unfortunately,
four  patients  (13.7%)  developed  Epstein-Barr  virus-related  B-cell  lymphoproliferative
disease (EBV-LPD). [36] This complication has significantly hindered the development of
siplizumab.  A  Phase  I  trial  of  siplizumab  combined  with  rituximab  and  dose-adjusted
etoposide,  prednisone,  vincristine,  cyclophosphamide  and  doxorubicin  (EPOCH)  for  T-
and NK cell  lymphoma is currently ongoing at the National Cancer Institute,  where the
rituximab is used to prophylaxis against the risk of EBV-LPD.
4.2. Anti-CD3 antibodies
CD3 represents a series of intermediate molecular weight polypeptide chains (CD3γ, CD3δ,
CD3ε and CDζ) closely associated with α and β-subunits of the T-cell receptor (TcR) that
recognizes antigen-peptide epitopes presented by MHC molecules in a class-restricted
manner. [37] The intracellular regions of the CD3-subunits represent the signaling domains of
the TcR complex that mediates T-cell activation. CD3 is expressed on most T-cells throughout
development and thus represents a pan-T-cell antigen. The vast majority of T-cell neoplasms
express CD3, although its expression may be reduced or lost in some lesions. [38]
Muromonab-CD3  (Orthoclone®,  OKT3;  Janssen  Pharmaceutica,  Ltd.),  a  murine  IgG2a
monoclonal antibody directed against the 20 kDa CD3ζ-subunit is approved for the reversal
of acute allograft rejection in patients undergoing cardiac, hepatic and renal transplants. [39]
It has also been used for the depletion of T-cells from stem cell and bone marrow allog‐
rafts to treat or reduce the risk of serious GvHD. [40] Administration of muromonab-CD3




lymphoid tissue through complement-mediated lysis,  ADCC, apoptosis and the re-direc‐
tion of T-lymphocytes to other compartments. [41] Binding of muromonab-CD3 to its target
receptor  also  stimulates  TcR  signaling,  activation  and  proliferation  of  T-cells  with  in‐
creased expression of HLA-DR and CD25.
In one report, a patient with refractory T-cell acute lymphoblastic leukemia that received
muromonab-CD3 experienced a dramatic, albeit transient decline in circulating lymphoblasts
and a reduction in splenomegaly. [42] Muromonmab-CD3 therapy is made difficult because
engagement of the antibody with CD3ζ increases TcR signaling and can result in the release of
inflammatory cytokines that can cause life-threatening cytokine release syndrome. In addition,
muromonab-CD3 is also mitogenic for T-cells and its use may risk increasing the proliferation of
malignant T-cells. Muromonmab-CD3 therapy is also associated with profound suppression of
cell-mediated immunity and increased risk of opportunistic infections and secondary malignan‐
cies including EBV-LPD, lymphoma, skin cancer and Kaposi’s sarcoma.
4.3. Anti-CD4 antibodies
CD4 is a 55 kDa membrane glycoprotein with four immunoglobulin-like domains, a hydro‐
phobic transmembrane domain and a long cytoplasmic tail. [43] CD4 acts as a co-receptor for
the TcR complex. It is expressed on helper and regulatory T-cells, and it recognizes antigens
presented by MHC class II molecules in association with the TCR. CD4 represents an attractive
target since the majority of the post-thymic T-cell malignancies manifest a CD4+ phenotype.
In phase I study, seven CTCL patients were treated with a chimeric antibody composed of
the IgG1κ human constant regions and the mouse variable regions directed against CD4
(anti-Leu3a). [44] Patients were dosed in cohorts of 10, 20, 40 or 80 mg intravenously twice
a week for three weeks. At the 80 mg dose, the antibody was detected in skin lesions and
also coating circulating CD4+ T-cells in the peripheral blood; however, with no significant
depletion of CD4+ cells was observed. In a second study, this group administered a single
intravenous  dose  of  another  chimeric  murine  anti-CD4  monoclonal  antibody,  cM-T412
(Centocor,  Inc.),  to  eight  previously  treated CTCL patients.  [45]  Following the  antibody
infusion there was a significant suppression of peripheral blood CD4+ cells in seven of eight
patients. Seven patients responded and the median duration of response was 25 weeks. One
patient developed a neutralizing anti-chimeric antibody response. Toxicity was grade 2 or
less and usually manifested as infusion reactions, mayalgias, and rashes.
More  recently,  zanolimumab  (HuMax-CD4®;  Genmab,  Inc.),  a  fully  human  IgG1κ  anti-
CD4 monoclonal antibody was shown to deplete CD4+ T-cells from the skin, reduce dermal
inflammatory infiltrates and induce remissions in psoriasis patients. [46] Zanolimumab was
evaluated in two separate phase II trials in a total of 47 CTCL/Sezary syndrome patients.
[47] Patients received between 280 and 980 mg weekly for up to 17 weeks. Zanolimumab
resulted in a dose-dependent and profound CD4+ lymphocytopenia; however, the recov‐
ery of CD4+ cells. Overall 13 of 38 (34.2%) CTCL patients and 2 of 9 (22.2%) patients with
Sezary cell leukemia responded to the antibody. Adverse events included nine infections
attributed to therapy. In a second phase II study, 21 adult patients with relapsed or refractory
CD4+ PTCL of non-cutaneous type were treated in a single-arm multicenter study, with
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weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. [48]. Objective tumor
responses were observed in 24% of the patients with two complete responses and three
partial responses. In general, the drug was well tolerated with no major toxicity. Zanolimu‐
mab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety
profile  in  this  poor-prognosis  patient  population,  suggesting  that  the  potential  benefit
combining zanolimumab with standard chemotherapy in the treatment of PTCL should be
investigated.
4.4. Anti-CD5 antibodies
CD5 (Leu-1) is a 67 kDa cysteine-rich scavenger receptor family glycoprotein expressed on
T-cells and the B1a subset of B-cells. [49, 50] CD5 acts as a co-receptor and appears to regulate
the  signaling strength of  the  TcR signaling response.  It  may also  play a  similar  role  in
modulating  B-cell  receptor  signaling.  [51]  Current  evidence  indicates  that  CD5 is  a  key
regulator  of  immune tolerance.  Two small  clinical  trials  have examined the use of  anti-
CD5 antibodies in patients with T-cell lymphoma. In one trial, 7 patients with refractory
Leu-1+ (CD5+) T-cell  lymphoma, six with CTCL and one with PTCL, were treated with
murine anti-Leu-1 monoclonal antibody at doses of 0.25 to 100 mg administered 2-3 times
per week. [52] A decrease in circulating T-cells was observed. The decline in T-cells was
short-lived  with  a  return  to  baseline  occurring  within  24-48  hours.  The  target  antigen
demonstrated down-modulation suggesting that CD5 might be a less suitable target for an
unmodified antibody strategy. Five short-lived responses were reported and not surprising‐
ly the majority of patients treated developed neutralizing antibodies. In another trial, T101,
a  murine IgG2a anti-CD5 monoclonal  antibody was administered to eight  patients  with
CD5+ T-cell malignancies, four of which had CTCL. [53] Short-lived clinical improvements
were  noted  in  two  CTCL patients.  Again,  the  induction  of  neutralizing  antibodies  was
limiting. More recent trials of CD5-targeted therapy have focused on treatment of B-cell-
induced autoimmune diseases and purging of T-cells from bone marrow to prevent GvHD
and have used immunotoxin conjugates of anti-CD5. [54-56]
4.5. Anti-CD25
CD25 (IL-2Rα) is the 55 kDa subunit of the interleukin-2 (IL-2) receptor, and plays a critical
role mediating immune-modulatory function of IL-2 in the activation of T- and B-lymphocytes,
NK-cells and macrophages. [57, 58]. Less than 5% of un-stimulated peripheral blood T-cells
expresses the IL-2Rα; however, it is highly expressed on activated T-cells and on many B- and
T-cell neoplasms such as ATL, ALCL, CTCL, hairy cell leukemia, and on the Reed-Sternberg
cells of Hodgkin’s lymphoma. [59]
In 1981, Uchiyama and coworkers generated murine anti-Tac that defined the human IL-2Rα
(CD25). [60] Daclizumab (Zenapax®; Hoffmann-La Roche, Inc.) is a recombinant monoclonal
antibody where murine antigen-binding regions of the anti-Tac molecule were joined to a
human immunoglobulin framework, approximately 90% of the murine IgG2a has been
replaced with a human IgG1κ sequence. [61] Daclizumab has the advantages of a low frequency




Tac, and the ability to mediate ADCC through its humanized Fc-domain. [62] It inhibits IL-2-
induced activation of T-cells and it is approved for the prophylaxis of renal allograft rejection
in combination with other immunosuppressive drugs.
Daclizumab up to 8 mg/kg was administered to ATL patients in one phase I/II trial. [63]
Cohorts of patients were treated with daclizumab 2 mg/kg on days 1 and 2, or 4, 6, or 8
mg/kg as a single intravenous dose every 2 or 3 weeks to complete six doses. Although
Daclizumab  showed  modest  clinical  activity  (2  partial  response  and  3  patients  with
improvement of their skin disease), flow cytometry analysis of the peripheral blood 72 hours
after the first dose and at weeks 2,  5 and 14 showed that ≥95% saturation of IL-2Rα on
circulating ATL cells  could be achieved and maintained.  In six  patients  that  underwent
lymph node fine needle aspiration, receptor saturation was documented in only half and it
was not maintained suggesting that the impeded access of large antibody molecules into
tumor is a potential blockade to receptor-directed therapy.
4.6. Anti-CD30 antibodies
CD30 is a cellular membrane protein member of the tumor necrosis factor receptor (TNFR)
family expressed on activated T- and B-cells. It is highly expressed on HL Reed–Sternberg (RS)
cells, in anaplastic large cell lymphoma (ALCL), embryonal carcinomas, and select subtypes
of B-cell derived, non-Hodgkin's lymphomas and mature T-cell lymphomas. The immuno‐
toxin brentuximab vedotin (Adcetris®, SGN-35) was approved by the FDA in 2011 and became
the first new treatment for HL in 30 years. Brentuximab vedotin is an antibody-drug conjugate
between the antitubulin agent monomethylauristatin E (MMAE) and the anti-CD30 monoclo‐
nal antibody cAC10. Clinical studies with unconjugated anti-CD30 antibodies have shown
disappointing clinical activity. [64] Objective responses were observed in 6% of patients with
HL who were treated with MDX-060 and in none of those treated with cAC10 (SGN-30).
However, the results of a pivotal phase II study of brentuximab vedotin in relapsed or
refractory HL were impressive [65]. In this study, 102 patients with refractory or relapsed
classical HL received brentuximab vedotin every 3 weeks for a median of 27 weeks. Almost
all patients exhibited a reduction in tumor volume with 34% complete response and 40% partial
response. A phase II multicenter trial evaluated the efficacy and safety of brentuximab vedotin
in relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) patients as CD30 is
uniformly expressed in ALCL. [66] Fifty-eight patients received brentuximab vedotin 1.8 mg/
kg intravenously every 3 weeks and 50 patients (86%) achieved an objective response, 33
patients (57%) achieved a complete remission (median duration 13.2 months) and 17 patients
(29%) achieved a partial remission. Grade 3 or 4 adverse events observed in ≥10% of patients
were neutropenia (21%), thrombocytopenia (14%), and peripheral neuropathy (12%). Based
on these studies, brentuximab vedotin received accelerated approval for the treatment of
Hodgkin lymphoma that has relapsed after autologous stem cell transplant and for the
management of relapsed ALCL. Currently multiple studies are evaluating combination of
brentuximab vedotin combined with standard chemotherapy options in management of both
newly diagnosed and relapsed refractory ALCL patients.
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4.7. Alemtuzumab (anti-CD52)
CD52 is a glycosylphosphatidylinositol (GPI)-anchored antigen expressed at high density on
normal and malignant T- and B-cells, NK cells, monocytes, macrophages, eosinophils and
epithelial cells of the male genital tract. It is not expressed on hematopoietic stem cells,
granulocytes, erythrocytes, platelets, or plasma cells. Alemtuzumab (Campath®) a humanized
rat monoclonal antibody targeting CD52 was approved by FDA for the treatment of relapsed/
refractory B-cell chronic lymphocytic leukemia (CLL). [67] Due to the presence of CD52 on T-
cells and the antibody’s ability to activate several mechanisms of cell death including ADCC,
CMC and apoptosis it is an attractive agent to study in T-cell malignancies.
T-cell prolymphocytic leukemia (T-PLL) carries a worse prognosis than CLL and has no
established standard therapy and thus constituted a fitting model to study alemtuzumab. An
initial trial in 39 T-PLL patients showed an overall response rate of 76%, including 60%
complete responses to alemtuzumab. [68] A subsequent study reported the experience with
alemtuzumab in 76 T-PLL patients. [69] The objective response rate was 51% with almost 40%
patients achieving complete response with median response duration of 8.7 months. The most
common treatment-related adverse events were acute infusion reactions. There were 2
treatment-related deaths, 15 infectious episodes in 10 patients during active treatment, and 8
patients experienced late-onset infections due to the long lasting lymphopenia associated with
alemtuzumab treatment.
These promising results in T-PLL lead to additional trials of alemtuzumab in both cutaneous
T-cell lymphoma and other systemic T-cell malignancies either as a single agent or combined
with chemotherapy. Single agent alemtuzumab is active in a variety of T-cell malignancies;
however, responses are not durable and the risks of immunosuppression and development of
opportunistic infections in patients poses a significant problem. In a phase II trial, alemtuzu‐
mab was administered to 22 patients with advanced mycosis fungoides/Sézary syndrome (MF/
SS). The overall response rate was 55%, with 32% of patients achieving a complete remission.
[70] Remarkably after treatment, Sézary cells were undetectable in blood in 6 of 7 (86%) SS
patients and pruritis significantly improved in responding patients. Patients with erythroder‐
ma responded better than patients with thick plaque disease or skin tumors.
In a pilot study, 14 patients with heavily pretreated peripheral T-cell lymphoma (PTCL) that
received alemtuzumab for a maximum of 12 weeks showed a response rate of 36%. [71] Toxicity
included cytomegalovirus (CMV) reactivation in 6 patients, pulmonary aspergillosis in 2
patients, and pancytopenia in 4 patients. Another trial reported on the efficacy of the combi‐
nation of alemtuzumab combined with cyclophosphamide, doxorubicin, vincristine and
prednisone (CHOP) as initial therapy for 24 PTCL patients. [72] The overall complete response
rate was 71% (17 patients) and 1 patient a had partial remission. Grade 4 neutropenia and CMV
reactivation was frequent. JC virus reactivation, invasive pulmonary aspergillosis, staphylo‐
coccal sepsis and pneumonia were also seen. In a recently reported phase II trial by the Dutch-
Belgian HOVON group, 20 T-cell lymphoma patients were treated with 30 mg of alemtuzumab
three times per week with every two week CHOP for eight courses. [73] The overall response
was 90% and the median overall survival and event-free survival were 27 and 10 months,




many patients ultimately still relapsed, and this treatment was associated with frequent serious
infection-related adverse events.
The combination of intravenous alemtuzumab 30 mg three times weekly and weekly pentos‐
tatin 4 mg/m2 was studied in 24 patients with a variety of T-cell leukemias and lymphomas.
[74] This trial showed an overall response rate of 54% with 11 complete responses and median
response duration was 19.5 months. As with other trials opportunistic infections due to severe
T-cell dysfunction were common in spite of antimicrobial prophylaxis.
4.8. Anti-CD122 (Mik-β1) antibodies
CD122 (IL-2R/IL-15Rβ) is a 75 kDa glycoprotein that constitutes the β-subunit shared by the
IL-2 and IL-15 receptors. During signal transduction, CD 122 and CD132, the common γ-chain
of type I cytokine receptors, recruit janus kinase (JAK), that in turn activates the signal
transducer and activator of transcription (STAT). Activated STAT transcription factors
enhances specific gene expression after translocation to nucleus. T-cell large granular lym‐
phocyte (T-LGL) leukemia commonly presents with anemia, neutropenia and less frequently
thrombocytopenia. IL-2 and IL-15 can stimulate T-LGL and NK cells and it is thought that the
clinical cytopenias seen in T-LGL leukemia are a result of the enhanced NK activity of the
leukemic cells. The Mik-β1 antibody (anti-CD122), directed against the IL-2R/IL-15Rβ, can
inhibit IL-15-mediated effects in vitro. [75]
In a phase I trial, 12 patients with T-LGL leukemia received the murine Mik-β1 antibody and
showed no responses in terms of decreases in T-LGL cell counts or improvement in their
cytopenias. [76] Greater than 95% saturation of CD122 on circulating T-LGLs was achieved in
all patients and down-modulation of CD122 was observed in seven patients. The lack of
response may be the result of the short half-life of the murine antibody. In addition, down-
modulation of CD122 after binding of the antibody reduced the amount of the receptor on the
surface of the LGL cells and might have impacted the efficacy of the Mik-β1 antibody. A phase
I safety and pharmacokinetic study of the humanized form of the antibody, HuMik-β1, in T-
LGL leukemia patients was recently completed, but the results are not available.
4.9. KW-0761 (anti-CCR4)
Chemokine receptor-4 (CCR4) is over expressed on several T-cell neoplasms in addition to its
normal expression on T-helper type 2 and regulatory T-cells. [77]. KW-0761 is a humanized
IgG1 monoclonal antibody with a defucosylated Fc region that markedly enhances ADCC due
to its increased binding affinity to the Fcγ receptor on effector cells. [78]. In a Phase I trial in
16 patients with relapsed CCR4-positive adult T-cell leukemia/lymphoma (ATL) or PTCL
received KW-0761 once a week for 4 weeks by intravenous infusion. Toxicities included
infusion reactions and skin rashes. The objective response rate was 31% with two complete
and three partial responses. [79] Recently a multicenter phase II study conducted on 28 patients
with relapsed ATL showed overall objective response rate of 50%, including eight complete
responses, with a median progression-free and overall survival of 5.2 and 13.7 months,
respectively. [80] The most common adverse events were infusion reactions (89%) and skin
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rashes (63%), which were manageable and reversible in all cases. Based on these results, a
multicenter randomized phase II trial is ongoing comparing KW-0761 with standard second-
line therapy according to investigator's choice of pralatrexate, gemcitabine and oxaliplatin, or
dexamethasone, cisplatin and cytarabine in previously treated relapsed ATL.
5. Conclusions
T-cell leukemias and lymphomas represent a heterogeneous group of uncommon diseases that
often present with advanced stage disease and systemic symptoms. Historically they have
been treated with combination chemotherapy similar to high-grade B-cell lymphomas;
however, outcomes have been poorer. One of the reasons for this may be the lack of effective
monoclonal antibody therapy for these diseases comparable to that of rituximab for the B-cell
disorders. A number of antibodies targeting surface receptors on T-cells are being clinically
studied. Alemtuzumab, a CD52-directed monoclonal antibody has demonstrated antitumor
activity as a single agent and in combination with chemotherapy, but with increased risk of
serious opportunistic infections. Zanolimumab and KW-0761 directed against CD4 and CCR4
expressed on T-cells, have also show an activity against CTCL and ATL, respectively and are
being studied in ongoing clinical trials and offer hope for the future for patients with T-cell
malignancies.
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